T helper 2 cell cytokine pathway (Th2 pathway)

The T helper 2 (Th2) cell cytokine pathway is a fundamental component of the adaptive immune system, primarily responsible for orchestrating type 2 immunity against extracellular parasites and allergens (1.1.1, 1.3.2). This pathway is characterized by the differentiation of naive CD4+ T cells into Th2 effector cells, a process driven by the master transcription factor GATA3 and signaling through the JAK-STAT pathway (1.1.1, 1.3.4). Once activated, Th2 cells secrete a signature profile of cytokines, including Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13), which promote B-cell class switching to IgE, eosinophil recruitment, and goblet cell mucus production (1.1.2, 1.1.5). While essential for host defense, chronic overactivation of the Th2 pathway is a central driver of allergic and inflammatory diseases such as asthma, atopic dermatitis, and eosinophilic esophagitis (1.3.1, 1.4.3). Therapeutic intervention typically involves monoclonal antibodies, such as dupilumab or mepolizumab, which target specific cytokines or their receptors to interrupt the inflammatory cascade and improve clinical outcomes in patients with Th2-high disease phenotypes (1.2.1, 1.4.1).

Other names

Type 2 immune pathwayTh2 cytokine axisType 2 inflammation pathwayTh2 differentiation pathway

Inhibition of type 2 cytokines (such as Interleukin-4, Interleukin-5, and Interleukin-13) or their respective receptors (such as Interleukin-4 receptor subunit alpha and Interleukin-5 receptor subunit alpha) to suppress eosinophilic inflammation, IgE production, and mucus hypersecretion.